Cutaneous T-Cell Lymphoma Recurrent Completed Phase 3 Trials for Pralatrexate (DB06813)

Also known as: T-Cell Lymphoma Relapsed / Recurrent T-Cell Lymphoma / Recurrent Cutaneous T-cell lymphoma / T-cell lymphoma recurrent / Relapsed T-Cell Lymphoma / T-cell lymphoma NOS recurrent

IndicationStatusPhase
DBCOND0136063 (Cutaneous T-Cell Lymphoma Recurrent)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03349333A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCLTreatment